Results 21 to 30 of about 202 (68)

Material Trends and Clinical Costings in Systematically Identified CDER‐Approved Nanomedicines

Advanced Therapeutics, Volume 7, Issue 10, October 2024.
To investigate translational challenges in nanomedicine research, an overview is provided for the last decade of nanomedicine development following a systematic analysis of publicly available data from Drugs@FDA and clinicialtrial.org, providing breakdowns and use cases relating to 37 approvals, as well as providing information regarding clinical trial
Thomas Ryan Jarrett, Lisette Pregelj, Craig Andrew Bell, Nicholas Lyle Fletcher, Kristofer James Thurecht   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Investing in vision:Innovation in retinal therapeutics and the influence on venture capital investment

Since the groundbreaking approval of the first anti-VEGF therapy in 2004, the retinal therapeutics field has undergone a remarkable transformation, witnessing a surge in novel, disease-modifying therapeutics for a broad spectrum of retinal diseases ...
Clark, Simon J; id_orcid, Mulder, Geert-Jan, Hristodorov, Dmitrij, Lohoff, Tim, Luneborg, Nanna   +4 more
core   +1 more source

CAR‐Aptamers Enable Traceless Enrichment and Monitoring of CAR‐Positive Cells and Overcome Tumor Immune Escape

Advanced Science, Volume 11, Issue 10, March 13, 2024.
a) The concept illustration of the CAR‐ap aptamer SELEX process. b) CAR‐ap aptamers used for traceless enrichment of CAR19‐T cells. c) CAR‐ap can specifically monitor CAR‐positive cells. d) CAR‐ap aptamers retarget CAR19‐T cells to CD19 antigen‐lost tumor cells. Abstract Chimeric antigen receptor (CAR)‐positive cell therapy, specifically with anti‐CD19
Hang Zhou, Tuersunayi Abudureheman, Wei‐Wei Zheng, Li‐Ting Yang, Jian‐Min Zhu, Ai‐Bin Liang, Cai‐Wen Duan, Kaiming Chen   +7 more
wiley   +1 more source

The etiology, pathogenesis, and current prevention/treatment for age-related macular degeneration [PDF]

2024Age-related macular degeneration (AMD) is a metabolic disease that is one of the most common leading causes of vision loss in elderly patients. The hallmark of this disease is the presence of lipid and protein deposits called drusen that accumulate ...
Lim, Perry
core  

Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities. [PDF]

Curr Ther Res Clin Exp
Durán-Cristiano SC, Ospina-Villa JD, Gijs M.   +2 more
europepmc   +1 more source

Izervay versus Syfovre: Two Rivals Recently Approved for Management of Geographic Atrophy. [PDF]

Ann Afr Med
Patel H, Kutikuppala LVS, Sharma S, Chavan M, Rangari G, Misra AK, Rao KS.   +6 more
europepmc   +1 more source

Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases. [PDF]

Int J Retina Vitreous
Jorge R, Rego MGB, Zupelli AS, Calado RT.   +3 more
europepmc   +1 more source

"Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy". [PDF]

Ann Med Surg (Lond)
Shakeel L, Khan A, Akilimali A.
europepmc   +1 more source

New horizons in geographic atrophy treatment: enthusiasm and caution surrounding complement inhibitors. [PDF]

BMJ Open Ophthalmol
Lai E, Lee T, Lee C, Schechet SA.
europepmc   +1 more source